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Background: Surgeons are usually exposed to high workloads leading to fatigue and stress. This not only increases
the likelihood of mistakes during surgery but also puts pressure on surgeons to use drugs to counteract fatigue,
distress, concentration deficits, burnout or symptoms of depression. The prevalence of surgeons taking
pharmacological cognitive enhancement (CE) or mood enhancement (ME) drugs has not been systematically
assessed so far.
Methods: Surgeons who attended five international conferences in 2011 were surveyed with an anonymous
self-report questionnaire (AQ) regarding the use of prescription or illicit drugs for CE and ME and factors associated
with their use. The Randomized Response Technique (RRT) was used in addition. The RRT guarantees a high degree
of anonymity and confidentiality when a person is asked about stigmatizing issues, such as drug abuse.
Results: A total of 3,306 questionnaires were distributed and 1,145 entered statistical analysis (response rate: 36.4%).
According to the AQ, 8.9% of all surveyed surgeons confessed to having used a prescription or illicit drug
exclusively for CE at least once during lifetime. As one would expect, the prevalence rate assessed by RRT was
approximately 2.5-fold higher than that of the AQ (19.9%; 95% confidence interval (CI), 15.9% to 23.9%, N = 1,105).
An even larger discrepancy between the RRT and AQ was observed for the use of antidepressants with a 6-fold
higher prevalence (15.1%; 95% CI, 11.3% to 19.0%, N = 1,099) as compared to 2.4% with the AQ. Finally, logistic
regression analysis revealed that pressure to perform at work (odds ratio (OR): 1.290; 95% CI, 1.000 to 1.666;
P = 0.05) or in private life (OR: 1.266; 95% CI, 1.038 to 1.543; P = 0.02), and gross income (OR: 1.337; 95% CI, 1.091 to
1.640; P = 0.005), were positively associated with the use of drugs for CE or ME.
Conclusions: The use of illicit and prescription drugs for CE or ME is an underestimated phenomenon among
surgeons which is generally attributable to high workload, perceived workload, and private stress. Such intake of
drugs is associated with attempts to counteract fatigue and loss of concentration. However, drug use for CE may
lead to addiction and to overestimation of one’s own capabilities, which can put patients at risk. Coping strategies
should be taught during medical education.
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Surgeons are often exposed to an excessive workload
leading to mental and physical exhaustion, for example,
fatigue, sleep deprivation (especially in shift work), burn-
out, and even to higher rates of suicide [1-5]. This in-
creases the likelihood of mistakes during surgery [6-9].
In order to maintain high cognitive performance, sur-
geons can come under pressure to counteract fatigue,
distress, concentration deficits, burnout or symptoms of
depression by the use of enhancing substances. Warren
and colleagues discussed possible reasons for surgeons
to consider the use of substances for cognitive enhance-
ment (CE) or mood enhancement (ME), including such
issues as internal (to maximize one´s own potential) and
external pressure (by the employer or the public), patient
safety or surgeons’ well-being [10]. However, there is no
scientific evidence so far that either external or internal
pressure leads to the consumption of prescription or
illicit drugs to cope with these stressors. Nevertheless,
performance enhancing drugs may be especially attrac-
tive to surgeons due to the fact that they appear to be a
time-saving and, to some extent, an effective and easy al-
ternative to more time-consuming coping strategies (for
example, napping, sleep, relaxation techniques, and so
on) or the use of coffee which may cause tachycardia
and worsening tremor [10,11].
Thus, the use of prescription and illicit drugs could be
a coping strategy to manage poor working conditions.
However, (psycho-) stimulants (amphetamines (AMPH),
methamphetamine, methylphenidate (MPH)), modafinil
as well as antidementives and antidepressants have no
consistent effects for CE or ME in healthy non sleep-
deprived subjects [12-20]. Nevertheless, reduction of
cognitive performance due to sleep deprivation is a
common problem in shift work. Stimulants and moda-
finil have been demonstrated to attenuate disruption in
cognitive performance and mood during night-shift
work and sleep deprivation [20-25]. Previous studies
revealed the use of stimulants and modafinil for CE pur-
poses among students having at least an immediate pro-
vigilant effect [14,26,27]. Beyond that, antidepressants
such as selective serotonin reuptake inhibitors (SSRI) are
known to be used for ME, although previous studies
showed no immediate or delayed mood enhancing effect
[18,28,29]. Furthermore, it is unclear whether ME affects
only mood or also other aspects such as self-esteem or
self-representation.
Previous studies among high school and university
students using anonymous questionnaires (AQ) have
shown prevalence rates for the use of prescription stim-
ulants (MPH) to be 0.8% and 2.9% for illicit stimulants
(AMPH) whereas 10.5% decided to use caffeine tablets
for CE [27,30,31]. Furthermore, an online poll conducted
by the journal Nature depicts a lifetime prevalence rateof 20% for stimulants, modafinil or beta blockers for CE
purposes among participating academics [32]. A recent
study using the Randomized Response Technique (RRT)
shows prevalence rates of even 20% for the use of pre-
scription and illicit drugs among university students for
CE [33]. Studies using RRT guarantee an especially high
degree of privacy, anonymity, and confidentiality when a
person is prompted to answer sensitive questions about
socially undesirable or illicit behavior [34-38].
This present survey reports the first data on prescrip-
tion and illicit drug use for CE and ME among surgeons,
together with usage association factors. We estimated
prevalence rates of CE and ME among surgeons using
AQ and RRT.Methods
The data for this study resulted from a survey con-
ducted in 2011 among 3,306 German-speaking sur-
geons who attended five international conferences of
the German Society of Surgery (Deutsche Gesellschaft
für Chirurgie). After the first conference, potential
participants were asked if they had been assessed be-
fore; those who had been were excluded from a second
participation.
Based on previous research about prescription and il-
licit drugs for CE, an AQ about the use of prescription
and illicit drugs for enhancing cognitive functions or
mood was developed and distributed to the participants
during the conferences. The AQ asked about the ‘non-
medical use of stimulants with the particular intention
of CE’ and ‘the non-medical use of antidepressants with
the particular intention of ME’ during lifetime, last year,
last month and last week (frequency). Furthermore, we
asked for the age of first use. Beyond that, the AQ in-
cluded questions about potential risk factors associated
with usage of drugs and questions about biometrical pa-
rameters (for example, gender, age, age of first use, and
so on.). We were mainly interested in healthy partici-
pants using drugs specifically for CE or ME. Therefore,
the data of participants with self-reported psychiatric
disorders (for example, depression, attention deficit/hy-
peractivity disorder, (ADHD)) who had physicians’ pre-
scriptions for any drug were excluded.
Participants were asked to drop the questionnaire into
black boxes after having filled in the questionnaire
anonymously.
The study was carried out according to the Principles
for Medical Research Involving Human Subjects accor-
ding to the Declaration of Helsinki. The study was appro-
ved by the local Ethics Committee (Landesärztekammer
Rheinland-Pfalz) (No. 837.321.08 (6318)). Participants
gave informed consent by returning the questionnaire and
were informed about this procedure in the introduction
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by the above mentioned local Ethics Committee.
The AQ contained questions about the use of drugs
for CE and ME as well as questions using RRT. After a
brief introduction about the RRT stressing the anonym-
ity of this technique, questions were presented to partici-
pants as follows:
Please consider a certain birthday (yours, your mother’s,
etc.). Is this birthday in the first third of a month (1st to
10th day)?
If yes, please proceed to Question A; if no, please
proceed to Question B.
Question A: Is this birthday in the first half of the
year (prior to the first of July)?
Question B: Did you ever use prescription and/or
illicit drugs (e.g. Methylphenidate, Modafinil, illicit
Amphetamines, and so on) without a medical need
for cognitive enhancement?
Note that only you know which of the two questions
you will answer
o Yes o No
For assessing the use of antidepressants for mood
enhancement, we modified Question B as follows: ‘Did
you ever use antidepressants without medical need
for enhancing your mood and/or self-esteem, self-
presentation?’
The interviewers are not able to know which question
the respondent has to answer. Therefore, participants
can reply honestly without compromising themselves.
Of all participants, 67.1% (245.25/365.25) received the
sensitive question (B) and 32.9% (120/365.25) the non-
sensitive question (A). Using the following formula
π^ s ¼ a 1 pð Þ πNp
the proportion of ‘yes’ responses with respect to the
sensitive questions can be estimated from proportion
a of total ‘yes’ responses in the sample. p denotes the
probability of receiving the sensitive question (Ques-
tion B; p = 67.1% of all participants received this
question). The probability of answering the non-sensitive
question (A) with ‘yes’ is πn = 49.6% (181.25/365.25). A
95% confidence interval (CI) for the unknown prevalence
can be computed from the sampling variance
Var π^ sð Þ ¼ a 1 að Þn p2
where n denotes the sample size [33,39].For example for a ¼ 328=1105≈0:30;
p ¼ 245:25=365:25≈0:67;
πN ¼ 181:25=356:25≈0:50; and
n ¼ 1105; this yields
π^s ¼ 328=1105 1 245:25=365:25ð Þ 181:25=365:25245:25=365:25
≈ 0:1993 ¼ 19:93%:
Var π^sð Þ ¼ 328=1105 1 328=1105ð Þ
1105 245:25=365:25ð Þ2 ≈ 0:000419:





Thus the 95% confidence interval is 19:93 1:96 2:05;
that is; ranges from15:91% to 23:95%:
Statistical analyses were performed with SPSS for
Windows, Version 17.0. Means are given with their
corresponding standard deviation (SD) (mean ± SE) and
Clopper-Pearson confidence intervals (95% CI). AQ ques-
tions were analyzed using a multiple logistic regression
analysis. For the regression, the variable selection proced-
ure was performed by using stepwise forward selection
with a selection level of 0.05. The variables which were
analyzed as potential multivariable predictors of the
use of prescription or illicit drugs for CE before for-
ward selection were (available parameters): pressure to
perform at work, pressure in private life, gross income,
gender, age, family status, living with children, type of
employer, employment status, hours of work, satisfac-
tion with professional success, evaluation of career oppor-
tunities, pressure to perform subjectively evaluated as
burdensome and pressure to perform subjectively evalu-
ated as harmful to health. Ordinal variables with five
or more categories (pressure to perform at work, pressure
in private life, gross income, pressure to perform subject-
ively evaluated as burdensome and pressure to perform
subjectively evaluated as harmful to health) were treated
as continuous variables. Table 1 shows the variables in-
cluded for the regression after forward selection; all vari-
ables which significantly influence the drug use for CE/
ME are listed in this table. There are no further variables
for which we adjust. The results are presented as odds
ratio (ORs) with confidence limits and P-values. The
regression has been analyzed by referring to cases without
missing values (complete case analysis).
Results
Participants´ characteristics
A total of 1,204 (36.4%) of 3,306 distributed question-
naires were returned. Of the participants, 61 had to be
excluded: 9 for not being a physician, 11 for having a
physician`s prescription for drugs because of mental
Table 1 Risk factors for the use of prescription or illicit drugs for CE among surgeons by multivariable analysis
Parameters OR 95 % confidence limits P-value
Pressure to perform at work 1.327 1.010 1.743 0.042
Pressure to perform in private life 1.252 1.015 1.543 0.036
Gross income 1.406 1.133 1.744 0.002
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answers. Thus, the data of 1,145 surgeons entered the
final statistical analysis. The mean weekly workload was
estimated to be 56.8 ± 13.0 hours. Of the respondents,
56.4% were surgeons in training, 21.5% senior surgeons
and 22.1% directors or deputy directors.
The pressure to perform optimally at the job was esti-
mated to be severe (3.3 ± 1.2 on a 6-point Likert scale,
0 = not at all, 5 = very much), judged to be moderate to
severely burdensome (2.6 ± 1.3) and moderate to severely
harmful (2.7 ± 1.3). For further details, see Table 2.
Lifetime-prevalence of CE and ME is higher than last-
year prevalence, which in turn is higher than last-month
and last-week prevalence rates (see Table 3 and 4). Dif-
ferences between last-year and last-month prevalence
rates for CE and ME are small, whereas the difference
between lifetime prevalence and last-year prevalence rate
is remarkably higher. Age of first use did not differ sig-
nificantly between prevalence rates. For more details on
lifetime-, last-year, last-month and last-week prevalence
rates, as well as for age of first use using the AQ, see
Tables 3 and 4.Prevalence rates of CE and ME measured by AQ
compared to the randomized response technique (RRT)
Prevalence rates measured by the RRT are considerably
higher than prevalence rates measured by AQ. Table 5
shows that with AQ, 8.9% of the surgeons confessed to
having used a prescription or illicit drug exclusively for
CE at least once during their lifetime. In contrast, the
corresponding RRT estimate was approximately 2.5-fold
higher than the AQ estimate, that is, 19.9% (95% CI,
15.9% to 23.9%, n = 1,105). An even larger discrepancy
between the RRT and AQ was observed for the use of
antidepressants with a 6-fold higher prevalence rate, that
is, 15.1% (95% CI, 11.3% to 19.0%, n= 1,099) as com-
pared to 2.4% with the AQ.Factors associated with the use of prescription and illicit
drugs for CE/ ME
Finally, a logistic regression analysis revealed that pres-
sure to perform at work (OR: 1.327; 95% CI: 1.010 to
1.743; P = 0.042) or in private life (OR: 1.252; 95% CI:
1.015 to 1.543; P = 0.036) and gross income (OR: 1.406;
95% CI: 1.133 to 1.744; P = 0.002) were positively associ-
ated with the use of drugs for CE or ME (see Table 4).Logistic regression analysis suggests that other factors
play no role in the use of prescription and illicit drugs:
gender (P = 0.809), age (P = 0.620), family status (P =
0.698), living with children (P = 0.720), type of employer
(P = 0.151), employment status (P = 0.820), hours of work
(P= 0.366), satisfaction with professional success (P =
0.829) and evaluation of career opportunities (P = 0.822).
Discussion
The AQ results of this study indicate that 8.9% of all
surveyed surgeons used prescription or illicit drugs with
the particular intention of CE by AQ. By contrast, the
RRT results showed a higher prevalence of 19.9%. Fur-
thermore, using AQ, 2.4% answered that they had al-
ready used antidepressants for ME whereas the RRT
revealed a prevalence of 15.1%. Furthermore, prescrip-
tion or illicit drug use for CE or ME was associated with
the pressure to perform at work or in private life and
with gross income.
On the one hand, there are substantial differences
regarding the prevalence rate in the present study.
On the other hand, there are significant differences
compared with previous studies of drug use for per-
formance enhancement. There are an increasing number
of studies dealing with ‘academic performance enhan-
cement’, ‘cognitive enhancement’ or ‘pharmacological
neuroenhancement’ regarding cognition (for example,
[10,26,27,32,40-42]).
Regarding prevalence rates and associated factors, it is
useful to consider several factors as follows: With the
exception of the present study, there exists a severe pau-
city of data about drug use for CE among employed
adults. DAK, a German health insurance company,
online surveyed via e-mail 20,000 employed members
(20- to 50-years old) with a response rate of 15%. Partici-
pants were asked about their use of various substances
for CE and mental well-being without medical need [43].
Without accurately distinguishing prescription and over-
the-counter drugs, the non-representative DAK study
showed a lifetime prevalence rate of 5%. Stated reasons
for usage were: ‘depressed mood’, ‘anxiety’, ‘nervousness’,
‘uneasiness’, ‘memory deficits’, ‘fatigue’, and ‘problems of
concentration’ [43]. These rationales seem to be the
same as among surgeons [1-5]. Furthermore, a non-
random online poll by the journal Nature which unfor-
tunately did not specify respondents, demonstrated that
20% of participants had already used prescription drugs
Table 2 Participants` characteristics












Participants living with children 525 (48.0%)
Participants living without children 568 (52.0%)
Type of employer:
University 315 (27.7%)
Hospital (other than University hospital) 636 (56.0%)
Doctor´s office/ Doctor´s surgery 159 (14.0%)
Other (for example, industry) 26 (2.3%)
Employment status:
Surgeons in training (1st to 5th year) 646 (56.4%)
Senior surgeons 246 (21.5%)
Directors/deputy directors 253 (22.1%)
Hours of work (per week)
Hours (Mean ± SD) 13 to 100 (56.77 ± 12.97)
Gross income:
<40,000 € 64 (5.7%)
40,000 to 100.000 € 544 (48.6%)
100,000 to 150.000 € 298 (26.6%)
150,000 to200.000 € 102 (9.1%)
>200,000 € 111 (9.9%)
Satisfied with professional success
Yes 975 (87.8%)
No 136 (12.2%)
Subjective evaluation of career
opportunities
Mean ± SD: 2.49 ± 0.94
1 = 126 (11.5%)
2 = 488 (44.7%)
3 = 342 (31.3%)
4 = 91 (8.3%)
5 = 44 (4.0%)
Pressure to perform on the job
Mean ± SD: 3.32 ± 1.18
0 = 32 (2.8%)
1 = 67 (5.9%)
2 = 131 (11.5%)
3 = 318 (27.9%)
Table 2 Participants` characteristics (Continued)
4 = 452 (39.7%)
5 = 138 (12.1%)
Pressure to perform in private life
Mean ± SD: 2.01 ± 1.26
0 = 140 (12.4%)
1 = 267 (23.7%)
2 = 329 (29.2%)
3 = 246 (21.9%)
4 = 118 (10.5%)
5 = 251 (2.2%)
Pressure to perform subjectively
evaluated as burdensome
Mean ± SD: 2.57 ± 1.28
0 = 62 (5.5%)
1 = 196 (17.3%)
2 = 260 (22.9%)
3 = 323 (28.4%)
4 = 238 (21.0%)
5 = 57 (5.0%)
Pressure to perform subjectively
evaluated as harmful to health
Mean ± SD: 2.72 ± 1.34
0 = 71 (6.3%)
1 = 158 (14.0%)
2 = 233 (20.6%)
3 = 299 (26.4%)
4 = 292 (25.8%)
5 = 78 (6.9%)
Use of 6-point Likert scale, 0 = not at all, 5 = very much in respect of the
following items: Subjective evaluation of career opportunities; Pressure to
perform; Subjective pressure to perform. Means are given with standard
deviation (SD).
Prevalence rates of cognitive enhancement (CE) and mood enhancement (ME)
measured by anonymous questionnaires (AQ).
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improve their focus for a specific task. MPH was the most
popular substance, followed by modafinil and beta bloc-
kers [32]. MPH and modafinil are also the most pre-
valently used drugs in our survey. This agrees with the
results of our study, although, admittedly, the surveyedTable 3 AQ results for prevalence rates of the use of
prescription drugs + illicit drugs for CE
Prescription
drugs + illicit drugs
N % Age (mean ± SD)
of first use
Last Week 8 0.84 25.00 ± 1.41
Last Month 13 1.36 24.40 ± 1.44
Last Year 29 3.03 24.47 ± 8.04
Lifetime 85 8.88 23.99 ± 6.21
Illicit drugs: Ecstasy, ephedrin, cocaine, illicit AMPH. AMPH, amphetamines;
CE, cognitive enhancement; AQ, anonymous questionnaire; N, number.
Table 4 AQ results for prevalence rates of the use of
antidepressants for ME
Prescription
drugs + illicit drugs
N % Age (mean ± SD)
of first use
Last Week 4 0.42 26.00 ± 0
Last Month 5 0.52 30.00 ± 5.66
Last Year 10 1.04 34.67 ± 9.02
Lifetime 23 2.40 38.67 ±10.65
AQ, anonymous questionnaire; ME, mood enhancement; N, number.
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sults match the RRT results of our study. Both surveys,
online polls as well as the present RRT study, guarantee a
relatively high level of anonymity. This may be one of the
most important aspects when assessing pharmacological
CE or ME, both potentially highly stigmatizing subjects.
Outside of these particular studies, only students’ sub-
stance use for academic performance enhancement has
been surveyed. A previous study by our research group
among 1,500 high school and university students (over
18 years) using AQ, assessed lifetime prevalence rates of
1.29% for prescription stimulants (MPH, AMPH) and
2.6% for illicit stimulants [27]. Regarding lifetime preva-
lence, we found that prevalence rates for stimulants in
the present study are slightly higher than in our earlier
students’ survey. This may be associated with the older
age of surgeons.
Furthermore, both studies excluded participants with
ADHD or other psychiatric disorders where prescribed
psychiatric medications were involved. Many other stu-
dies did not exclude these ‘patients’, revealing higher
prevalence rates including those where participants mis-
use their own prescribed medication [40].Table 5 AQ and RRT results for lifetime prevalence rates of p
(CE) or mood enhancement (ME)
Study technique
Substance use for CE/ ME: AQ
(n= 957)
Any prescription or illicit drug 8.9% (n = 85)
Methylphenidate (MPH) 2.5% (n = 24)
Amphetamine pills 2.6% (n = 25)
Illicit amphetamines 0.9% (n = 9)
Modafinil 2.2% (n = 21)
Ecstasy 0.6% (n = 6)
Cocaine 1.6% (n = 15)
Ephedrin 1.2% (n = 11)
Antidementive drugs 0.3% (n = 3)
Atomoxetin 0.6% (n = 6)
Any antidepressant 2.4 (n = 23)
Lifetime prevalence rates of prescription or illicit drug use for CE and antidepressan
to the Randomized Response Technique (RRT). Means are given with standard deviA meta-analysis by Wilens and colleagues examining
prevalence rates of stimulant misuse included 21 US
studies with 113,000 participants revealing a past-year
prevalence rate of 5% to 9% in grade and high schools
and 5% to 35% in college-age individuals [40]. For this
important meta-analysis which included many signifi-
cant studies about stimulant misuse among students, CE
is only a side aspect of the study. This explains the sub-
stantially higher (past-year) prevalence rate compared to
the present study. However, ‘to concentrate’ and ‘im-
prove alertness’ have been salient participants’ reasons
for misuse of stimulants.
The most recent study about CE among 2,600 stu-
dents using the RRT shows a one-year prevalence rate of
20% for the non-medical use of prescription and illicit
drugs for CE [33]. These results show a comparable
prevalence to those of the present study.
Beyond that, Partridge and colleagues revealed that a
high percentage of the public media portrayed CE as
common which accords with our high prevalence rate
for CE [42]. However, this finding contrasts with that of
our survey study of the same group among university
students leading to the assumption of a ‘phantom de-
bate’ [44,45].
While we were not able to show a significant influence
of gender on the use of potential CE- or ME-substances,
Dietz and colleagues revealed that significantly more
male than female students used prescribed or illicit
drugs for CE. Our results do not confirm this finding.
The literature is somewhat inconsistent on this subject.
For the illicit use of prescription ADHD medications
among college students, DeSantis and colleagues found
a significantly higher prevalence rate in male than in fe-
male students [46], whereas Teter and colleagues foundrescription or illicit drug use for cognitive enhancement
Age of first use of enhancement
RRT (mean ± SD)
(n= 1,102) (according to AQ)










15.1% 38.7 ± 10.7
ts for ME among 1,143 surgeons by anonymous questionnaire (AQ) compared
ation (SD).
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use among college students [47]. However, studies focus-
ing upon this particular association in the context of a
different surveyed group from that of the present study,
suggest higher risk behaviors in male compared to fe-
male subjects [33,48].
Surveyed surgeons answered that their age of first use
of prescription or illicit drugs for CE was 24.0 years.
However, our previous study among 1,500 students re-
vealed 17 to 18 years to be the age of first use of pre-
scription or illicit drugs for CE [27]. This is almost 5 to
6 years younger than among surgeons, who themselves
had been medical students and later trainee surgeons,
decades before. However, study participants are 43 years
old (mean) which may imply that two decades ago, the
use of CE drugs started substantially later in life. Beyond
that, first use of antidepressants for ME was 39 years
(mean) compared to an average of 24-year-old partici-
pants using CE drugs for the first time.
Methodologically, all these studies only allow an indir-
ect comparison of different survey methods. The present
study allows us for the first time to compare AQ ques-
tions with RRT questions in one single integrated survey
about drug use. In this respect, a previous meta-analysis
of 38 RRT validation studies by Lensvelt-Mulders and
colleagues reported that RRT provides more valid data
than other survey methods. This strengthens the validity
of the RRT prevalence rates of 19.9% for CE and 15.1%
for ME [49]. This underlines the relevance of the survey
method in general. In particular, it strengthens the valid-
ity and reliability of the higher RRT results of 19.9% and
15.1% for CE and ME compared to the lower prevalence
rates using direct questions.
We were able to show that pressure to perform at
work or in private life, together with gross income, are
positively associated with the use of prescription or illicit
drugs for CE or ME and are the only factors associated
with drug use for this purpose. Further hypothesized
factors were revealed to play no role in the use of pre-
scription or illicit drugs for CE. We found a positive as-
sociation of pressure to perform at work or in private
life and gross income with the use of drugs for CE. How-
ever, we cannot interpret this finding as a general proof
of a direct causal relationship between feeling pressure
and the use of CE substances. Furthermore, this associ-
ation is not tenable for professional life in general. Such
factors should be addressed in detail in further studies.
At least to our present knowledge, there are no data
from empirical studies which allow meaningful compari-
son with our data: studies of students’ drug use focusing
on CE as well as the previously cited Nature poll did not
examine these factors.
Surgeons should know about the effects and side-
effects of the substances used for CE or ME, at leastregarding prescription drugs, such as methylphenidate,
amphetamine tablets (for example, AdderallW), atomoxe-
tine, modafinil, antidementive drugs and antidepressants.
A survey study by Partridge and colleagues showed that
university students already seem to have a realistic idea
of the effects and side-effects [44]. According to ran-
domized controlled trials (RCTs), reviews and meta-
analyses there are almost no pro-cognitive effects re-
garding normal healthy non-sleep-deprived subjects on
simple and higher cognitive domains [12-17].
Nevertheless, stimulants and modafinil have enhancing
effects on simple cognitive domains, such as fatigue,
vigilance, psychomotor skills and reaction time in sleep-
deprived subjects; furthermore, there are slightly pro-
cognitive effects on higher cognitive domains and, beyond
that, stimulants have subjective ‘pro-effects’ [12,14,19-25].
One can presume that the effects on higher cognitive skills
are indirect effects which are mediated via simple cogni-
tive skills, for example, vigilance. The fact that sleep
deprivation leads to clearer results supports this hypo-
thesis [12].
One would expect surgeons to know these limited ef-
fects and to avoid the use of these prescription and illicit
drugs for CE. However, every fifth surgeon has already
used these drugs. We can only speculate about the rea-
sons. On the one hand, surgeons may not know the
missing pro-cognitive effects or overestimate the effects
of such drugs. On the other hand, knowledge – and even
overestimation – about pro-cognitive effects in sleep-
deprived subjects only confirms that sleep deprivation is
a common phenomenon among surgeons.
Beyond that, antidepressants (such as SSRI) have no
mood enhancing effect in normal healthy subjects at all
[12,18]. Nevertheless, 15% have already used antidepres-
sants for ME, which may indicate missing knowledge
about the effects of antidepressants in normal healthy
subjects or overestimation of the putative effects.
Another important factor is the side-effect profile and
safety risks of amphetamines which have to be consid-
ered. Beyond severe side-effects which are described in
package-inserts accompanying these drugs and the re-
sults of RCTs, reviews and meta-analyses (for example,
jitteriness, agitation, cardiologic side effects, such as
tachycardia, hypertension, gastro-intestinal side effects,
such as stomach ache, diarrhea, and so on), stimulants
can cause addiction and further addictive behavior. Also,
the misuse of illicit drugs and prescription drugs without
prescription is a federal offense.
A number of limitations of the present study are worth
identifying here. We obtained a response rate of 36.4%
which is a low response rate compared to previous stu-
dies using RRT (for example, [27,33]). However, ques-
tionnaires were distributed during conference breaks in
huge buildings, so that we were hardly able to control
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the questionnaires to the black boxes provided. Further-
more, substance use – or even misuse – can be considered
a highly stigmatizing subject leading to low response rates.
Thus, a response rate of 36.4% may be considered re-
latively high and comparable to other studies assessing
stigmatizing subjects with anonymous questionnaires
[36]. However, the response rate of 36.4% together with
the non-random sample limits the generalizability of our
findings.
Another important factor is the likelihood of a partici-
pation bias: Since the response rate is only one third, we
do not know in particular whether subjects with more
positive attitudes or more negative attitudes on the topic
participated disproportionately which may have caused a
response bias. Since many more male subjects partici-
pated in our study, a potential gender bias exists. This
may explain why we did not find gender differences in
prevalence rates whereas earlier studies including our
own have partly shown that male subjects more often
used drugs for CE than female subjects.
Beyond that, we asked surgeons for the non-medical
use of stimulants for CE and antidepressants for ME.
However, we did not specifically ask for the context of
use, for example, whether surgeons had used it directly
prior to surgical interventions.
Conclusions
The use of illicit and prescription drugs for CE or ME is
an underestimated phenomenon among surgeons. The
present results indicate that about 15% to 20% of sur-
geons have used drugs for CE or ME at least once dur-
ing their lifetimes. This may be attributed to high
workload and perceived work-related and private stress.
Substances such as modafinil seem to counteract fa-
tigue and loss of concentration and thus may provide
simple pharmacological help for stressed surgeons. How-
ever, pro-cognitive effects on higher cognitive domains
are very limited. Furthermore, the side effects and effects
of long-term use (for example, misuse, addiction) of
such drugs seem to be underestimated by users. Beyond
that, stimulant use may put patients at risk given the fact
that previous research has shown that stimulants may
lead to overestimation of one’s own capabilities. Both
factors may be harmful for users. The contemporary de-
bate on cognition-enhancing drugs requires a broader
data base on consumption rates in populations at risk,
together with careful studies of drug (side) effects to
substantiate discussions of ethical and legislative aspects.
Therefore, I) information about the restricted usefulness
and risks of the use should be provided, II) guidelines on
how to deal with drug use among employees who have
contact with patients have to be provided, and III) infor-
mation about, and the development of, relevant copingstrategies has to become an integral part of medical
education.
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